Have a Read

B

Brad

New member
I Hope this link works..

A lot of You may get these same E mails from CFF.
Check out the 2 videos on the Cf Cillia and Non Cf.


<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
I Hope this link works..

A lot of You may get these same E mails from CFF.
Check out the 2 videos on the Cf Cillia and Non Cf.


<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
I Hope this link works..

A lot of You may get these same E mails from CFF.
Check out the 2 videos on the Cf Cillia and Non Cf.


<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
I Hope this link works..

A lot of You may get these same E mails from CFF.
Check out the 2 videos on the Cf Cillia and Non Cf.


<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
I Hope this link works..
<br />
<br /> A lot of You may get these same E mails from CFF.
<br /> Check out the 2 videos on the Cf Cillia and Non Cf.
<br />
<br />
<br /> <a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/aboutCFFoundation/Publications/connections/june2009/BasicDefect.cfm">http://www.cff.org/aboutCFFoun...ne2009/BasicDefect.cfm</a>
 
B

Brad

New member
This is the Part that really has me interested.

( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
B

Brad

New member
This is the Part that really has me interested.

( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
B

Brad

New member
This is the Part that really has me interested.

( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
B

Brad

New member
This is the Part that really has me interested.

( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
B

Brad

New member
This is the Part that really has me interested.
<br />
<br /> ( She noted that experts never expected that patients with preexisting lung damage would see such drastic improvements when taking a drug like VX-770.)
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.

According to the CFF website:

"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.

Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?

Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."

This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...

"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."

*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.

According to the CFF website:

"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.

Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?

Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."

This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...

"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."

*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.

According to the CFF website:

"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.

Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?

Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."

This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...

"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."

*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.

According to the CFF website:

"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.

Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?

Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."

This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...

"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."

*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*

<a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
J

Jeana

New member
Actually, they are doing a clinical trial to see if it works on Delta F508, as well. Our clinic is participating.
<br />
<br />According to the CFF website:
<br />
<br />"VX-770, the most advanced of the two compounds, is known as a potentiator and is designed to allow CFTR located at the cell surface to function correctly.
<br />
<br />Why wasn't the Delta F508 mutation chosen for the Phase 2 VX-770 clinical trials?
<br />
<br />Because G551D is already located at the cell surface, these patients have the greatest potential to benefit from treatment with VX-770."
<br />
<br />This means, that if the CFTR was located at the cell surface, it might work for Delta F508. So, if we use the VX-809 and the VX-770, Delta F508s might have very good results, since...
<br />
<br />"Vertex is also developing VX-809, known as a corrector, which is designed to move defective CFTR to its proper place in the cell."
<br />
<br />*In other words, VX-809 should move the CFTR to the cell surface and VX-770 should correct the CFTR at the cell surface.*
<br />
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/FAQs/VX-770/">http://www.cff.org/research/Cl...lResearch/FAQs/VX-770/</a>
 
You must log in or register to reply here.
Top